2023-509732-25-00已完成2 期
A dose-esalation phase I/II study in patients with RAS-mutated metastatic colorectal cancer to investigate safety and clinical actvitiy of the triple combination of: MEK-inhibitor binimetinib, pan-EGFR inhibitor lapatinib and the microtubule targeting agent (MTA) vinorelbine (RASTRIC)
Universitair Medisch Centrum Utrecht1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年9月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- For the phase I dose-escalation trial, the primary endpoint is the incidence of DLTs leading to a RP2D. The RP2D of the triplet will be the MTD which is defined as the dose level that can be given to 6 subjects such that not more than 1 subject experiences a DLT
研究概览
简要总结
Phase I dose escalation: To determine safety and the recommended phase II dose (RP2D) of the triple combination. Phase II: To determine efficacy of the triplet combination defined by objective response rate according to RECIST 1.1.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological proof of CRC
- •Able and willing to undergo a tumor and skin biopsy prior to start and after two weeks on therapy. Tumor biopsy should be histological. Cytological biopsies are not accepted
- •All toxicities related to prior treatment should have resolved to CTCAE grade 1 or less (excluding alopecia)
- •Life expectancy > 3 months allowing adequate follow up of toxicity evaluation and antitumor activity
- •Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration and agree to use effective contraception, throughout the treatment period, and for 4 months after the last dose of study treatment
- •Adequate organ functions as defined by table
- •Table 2 Definitions for adequate baseline organ function System Laboratory Values Hematologic Absolute neutrophil count ≥ 1.5 x 109/L Hemoglobin ≥ 6.0 mmol/L Platelets ≥ 100 x 109/L PT/INR and aPTT within normal limits (unless anticoagulant treatment or patient unable to undergo tumor biopsy) Hepatic Total bilirubin ≤ 1.5 x ULN AST and ALT ≤ 2.5 x ULN or ≤ 5x ULN in case of liver metastases Albumin ≥ 30.0 General Lactate dehydrogenase ≤ 2x ULN Renal Serum creatinine ≤ 1.5 x ULN Or Calculated creatinine clearance by Cockcroft-Gault formula: ≥ 50 mL/min Cardiac Left Ventricular Ejection Fraction (LVEF) by ECHO or MUGA ≥ 50%
- •After failure of a minimum of 2 lines of standard of care regimens. Prior lines of treatment must include: a minimum of 2 lines of prior systemic treatment for metastatic disease, including at least fluoropyrimidine, oxaliplatin and irinotecan-based treatment (unless contra-indications for either oxaliplatin and/or irinotecan). Adjuvant treatment completed < 6 months before development of metastatic disease will be counted as 1st line for metastatic disease.
- •Written documentation of a known pathogenic RAS mutation
- •Age ≥ 18 years
- •Able and willing to give written informed consent
- •Measurable disease according to RECIST 1.1
- •WHO performance status of 0 or 1
- •Able to swallow and retain orally administered medications and does not have clinically significant gastrointestinal abnormalities that may alter absorption (e.g. malabsorption syndrome, major resection of the stomach or bowel, or ileostomy)
- •Able and willing to undergo blood sampling
排除标准
- •Any treatment with investigational drugs within 30 days or 5 half-lives prior to receiving the first dose of investigational treatment
- •Patients who have undergone any major surgery within the last 3 weeks prior to starting study drug or who would not have fully recovered from previous surgery
- •Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients
- •Patients with known, active, hepatitis B (HBV) or C virus (HCV)
- •Patients with retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), or with a history of uveitis, retinal vein occlusion, central serous retinopathy, or retinal detachment
- •Patients with left ventricular ejection fraction (LVEF) < 50%
- •History or evidence of cardiovascular risk including any of the following: • A QT interval corrected for heart rate using the Bazett’s formula (QTcB) > 480 msec. • History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible. • History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization. • History of or current congestive heart failure ≥ class II as defined by the New York Heart Association. • Treatment refractory hypertension defined as a blood pressure of systolic > 150 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by one maximally dosed anti-hypertensive therapy. • Patients with intra-cardiac defibrillators.
- •Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study
- •Known hypersensitivity to one of the study drugs
- •Use of any live vaccines against infectious diseases (e.g. varicella, pneumococcus or yellow fever) within 4 weeks of initiation of study treatment
- •Use of prohibited co-medication or herbs and inability to discontinue this treatment or switch to an alternative drug at least 7 days prior to starting study treatment (see paragraph 5.8)
- •History of another malignancy. Exceptions: Patients who have been disease-free for at least 3 years after treatment with curative intent, or patients with a history of completely resected nonmelanoma skin cancer, in situ carcinoma of the cervix and/or patients with indolent completely resected second malignancies are eligible
- •Symptomatic or untreated leptomeningeal disease
- •Symptomatic brain metastases. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 6 weeks) are allowed to enroll. Radiotherapy for brain metastases must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive anti-epileptic drugs or corticosteroids
- •Patients previously treated with combination treatment of drugs known to interfere with EGFR, HER-2, HER-3, HER-4, or MAPK- and PI3K-pathway components, including inhibitors of PTEN, PI3K, AKT, mTOR, BRAF, MEK, and ERK. Single agent targeted therapies interfering with these pathways are allowed for inclusion in phase I. Exclusion criteria in phase II: patients previously treated with drugs known to interfere with EGFR, HER-2, HER-3, HER-4, or MAPK- and PI3K-pathway components, including inhibitors of PTEN, PI3K, AKT, mTOR, RAS, BRAF, MEK, and ERK, both as single agent or in combination
- •History of interstitial lung disease or pneumonitis
- •Women who are pregnant or breast feeding
- •Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are condom, sterilization, other barrier contraceptive measures preferably in combination with condoms)
- •Radio-, immuno- or chemotherapy within the last 4 weeks prior to receiving the first dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed
结局指标
主要结局
For the phase I dose-escalation trial, the primary endpoint is the incidence of DLTs leading to a RP2D. The RP2D of the triplet will be the MTD which is defined as the dose level that can be given to 6 subjects such that not more than 1 subject experiences a DLT
For the phase I dose-escalation trial, the primary endpoint is the incidence of DLTs leading to a RP2D. The RP2D of the triplet will be the MTD which is defined as the dose level that can be given to 6 subjects such that not more than 1 subject experiences a DLT
For the phase II trial the primary endpoint is objective response rate according to RECIST 1.1
For the phase II trial the primary endpoint is objective response rate according to RECIST 1.1
次要结局
- the pharmacokinetic profile of the triple combination, safety and tolerability (frequencies of AEs, dose reductions) and additional anti-tumor efficacy parameters including clinical benefit rate and progression-free survival
研究者
Jeanine Roodhart
Scientific
Universitair Medisch Centrum Utrecht
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
2 期
A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with advanced non-small cell lung cancer (NSCLC)Non-small Cell Lung Cancer2024-519344-32-00BioNTech SE24
招募中
3 期
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk MDS2022-500479-29-00Celgene Corp.166
招募中
1 期
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
已完成
1 期
QTc Assessment in a Single-Dose Study of Hydronidone CapsulesHepatic FibrosisNCT07263152Beijing Continent Pharmaceutical Co, Ltd.48